Auro Labs.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE292C01011
NSEID:
BSEID: 530233

INR

246.00

-3.8 (-1.52%)

BSENSE

Dec 18

BSE+NSE Vol: 709

{
  "main_header": {
    "sid": 239365,
    "name": "Auro Labs.",
    "stock_name": "Auro Labs.",
    "full_name": "Auro Laboratories Ltd",
    "name_url": "stocks-analysis/auro-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "246.00",
    "chg": -3.8,
    "chgp": "-1.52%",
    "dir": -1,
    "prev_price": "249.80",
    "mcapval": "156.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 530233,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE292C01011",
    "curr_date": "Dec 18",
    "curr_time": "",
    "bse_nse_vol": "709 ",
    "exc_status": "Active",
    "traded_date": "Dec 18, 2025",
    "traded_date_str": "2025 12 18",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/auro-labs-239365-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Auro Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-auro-labs-fallingrising-3759016",
        "imagepath": "",
        "date": "2025-12-16 00:31:45",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Relative Performance Against Benchmarks</strong></p>\n<p>Auro Laboratories has demonstrated remarkable resilience and growth over various time horizons. While the broader Sensex index has delivered modest gains, the stock has outpaced it significantly. Over the past week, Auro Laboratories surged by 8.90%, compared to the Sensex’s marginal 0.13% rise. This trend extends over longer periods, with the stock appreciating 12.90% in the last month against the Sensex’s 0.77%, and a 13.04% gain over the past year compared to the benchmark’s 3.75%. Most impressively, the company’s three-year and five-year returns stand at 251.11% and 213.63% respectively, dwarfing the Sensex’s 37.89% and 84.19% gains over the same periods. These figures highlight the stock’s strong growth trajectory and invest..."
      },
      {
        "title": "Auro Labs. Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/auro-labs-upgraded-from-strong-sell-to-sell-by-marketsmojo-on-30-sep-2025-3746471",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AuroLabs_mojoScore_3746471.png",
        "date": "2025-12-04 11:08:19",
        "description": "Auro Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators, including valuation concerns and subdued financial trends, which continue to shape investor perspectives."
      },
      {
        "title": "Auro Laboratories Surges with Unprecedented Buying Interest, Hits Upper Circuit",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/auro-laboratories-hits-upper-circuit-amidst-unprecedented-buying-frenzy-3718286",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AuroLaboratorie_only_buyers_3718286.png",
        "date": "2025-11-20 14:20:29",
        "description": "Auro Laboratories Ltd has witnessed extraordinary buying momentum today, registering a sharp surge that propelled the stock to hit its upper circuit limit. The absence of sellers and a queue filled exclusively with buy orders signal a potential multi-day circuit scenario, underscoring robust investor interest in this Pharmaceuticals & Biotechnology company."
      },
      {
        "title": "Auro Laboratories Shows Stable Performance Amidst Mixed Financial Results and Market Resilience",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/auro-laboratories-financial-trend-improves-from-negative-to-flat-amid-stabilizing-performance-3701175",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AuroLaboratorie_fintrenddot_3701175.png",
        "date": "2025-11-14 11:00:37",
        "description": "Auro Laboratories has reported stable financial performance for the quarter ending September 2025, with net sales reaching Rs 11.61 crore and significant improvements in key metrics. Despite a decline in PAT for the nine-month period, the company has outperformed the Sensex over the past three years."
      },
      {
        "title": "Auro Laboratories Q2 FY26: Profit Recovery Masks Deeper Structural Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/auro-laboratories-q2-fy26-profit-recovery-masks-deeper-structural-concerns-3712148",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AuroLaboratorie_quaterlyResult_3712148.png",
        "date": "2025-11-14 09:19:50",
        "description": "Auro Laboratories Ltd., a Mumbai-based generic Active Pharmaceutical Ingredients manufacturer specialising in anti-diabetic compounds, reported a return to profitability in Q2 FY26 with net profit of ₹0.72 crores, reversing the ₹0.11 crore loss recorded in the previous quarter. However, the modest absolute profit figure and concerning long-term trends continue to weigh on investor sentiment, with the stock trading at ₹228.00 and carrying a market capitalisation of just ₹142.10 crores."
      },
      {
        "title": "How has been the historical performance of Auro Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-auro-labs-3698875",
        "imagepath": "",
        "date": "2025-11-13 23:15:19",
        "description": "Answer:\nThe historical performance of Auro Labs shows a consolidated net profit of 1.84 crore for the year ending March 2025, with total operating income of 19.40 crore. The operating profit margin, excluding other income, stands at 17.58%, while the profit after tax margin is 9.48%. The company has total liabilities of 99.10 crore, with long-term borrowings increasing significantly to 30.79 crore from previous years. The total assets have also risen to 99.10 crore, reflecting growth in shareholder's funds, which reached 42.97 crore. \n\nBreakdown:\nIn the fiscal year ending March 2025, Auro Labs reported a total operating income of 19.40 crore, with a net profit of 1.84 crore, indicating a profit after tax margin of 9.48%. The operating profit, excluding other income, was 3.41 crore, leading to an operating profit margin of 17.58%. The company's total liabilities increased to 99.10 crore, driven by a rise in ..."
      },
      {
        "title": "Why is Auro Labs. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-auro-labs-fallingrising-3698493",
        "imagepath": "",
        "date": "2025-11-13 21:41:54",
        "description": "As of 13-Nov, Auro Laboratories Ltd's stock price is rising, currently at Rs 219.40, reflecting an increase of Rs 36.55 or 19.99%. The stock has shown strong performance today, outperforming its sector by 19.78% and opening with a gain of 6.64%. It reached an intraday high of Rs 219.40 and has traded within a wide range of Rs 30. However, despite this positive movement, there has been a notable decline in investor participation, with delivery volume falling by 25.86% compared to the 5-day average. Year-to-date, the stock is down 17.86%, but it has performed well over the past three years with a return of 183.28%.\n\nIn the broader market context, Auro Laboratories Ltd's short-term return of 17.45% over the past week significantly outpaces the Sensex, which has only increased by 1.40% in the same period. This indicates that the stock is gaining traction relative to the market. However, the year-to-date perform..."
      },
      {
        "title": "Auro Laboratories Ltd Surges 19.99% Today, Reaching Intraday High of Rs 219.4",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/auro-laboratories-ltd-surges-1999-today-reaching-intraday-high-of-rs-2194-3697536",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AuroLaboratorie_only_buyers_3697536.png",
        "date": "2025-11-13 11:30:19",
        "description": "Auro Laboratories Ltd is experiencing notable buying activity, with a significant intraday surge. The stock has shown strong weekly gains, contrasting with its recent performance over longer periods. Current investor interest may be linked to developments in the pharmaceutical sector, contributing to heightened trading volatility."
      },
      {
        "title": "How has been the historical performance of Auro Labs.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-auro-labs-3695068",
        "imagepath": "",
        "date": "2025-11-13 00:06:02",
        "description": "Answer:\nThe historical performance of Auro Labs shows a significant decline in net sales and profits over the past few years, particularly in the latest fiscal year ending March 2025.\n\nBreakdown:\nAuro Labs reported net sales of 19.40 Cr in March 2025, a sharp decrease from 53.64 Cr in March 2024 and 52.89 Cr in March 2023, indicating a downward trend in revenue. The total operating income followed a similar pattern, dropping to 19.40 Cr in March 2025 from 53.64 Cr in the previous year. The company's operating profit (PBDIT) also fell to 4.07 Cr in March 2025, down from 12.17 Cr in March 2024, reflecting a declining operating profit margin of 17.58%. Profit before tax decreased to 1.88 Cr in March 2025 from 10.35 Cr in March 2024, leading to a profit after tax of 1.84 Cr, down from 7.79 Cr. The total assets of Auro Labs increased to 99.10 Cr in March 2025 from 85.73 Cr in March 2024, while total liabilities ..."
      }
    ],
    "total": 133,
    "sid": "239365",
    "stock_news_url": "https://www.marketsmojo.com/news/auro-laboratories-239365"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "14-Nov-2025",
      "details": "Auro Laboratories Limited has submitted clippings of Newspaper Publications of the unaudited financial Results for the quarter and half year ended September 30 2025.",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025",
      "datetime": "12-Nov-2025",
      "details": "Auro Laboratories Limited has submitted unaudited Financial Results for the quarter and half year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Grant Of Certificate Of Good Manufacturing Practices From World Health Organisation (WHQ).",
      "datetime": "12-Nov-2025",
      "details": "Auro Laboratories Limited wishes to inform that Company has received World Health Organization - Good Manufacturing Practices (WHO-GMP) Certifcate from Food & Drug Administration.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Auro Labs. falling/rising?

2025-12-16 00:31:45

Strong Relative Performance Against Benchmarks

Auro Laboratories has demonstrated remarkable resilience and growth over various time horizons. While the broader Sensex index has delivered modest gains, the stock has outpaced it significantly. Over the past week, Auro Laboratories surged by 8.90%, compared to the Sensex’s marginal 0.13% rise. This trend extends over longer periods, with the stock appreciating 12.90% in the last month against the Sensex’s 0.77%, and a 13.04% gain over the past year compared to the benchmark’s 3.75%. Most impressively, the company’s three-year and five-year returns stand at 251.11% and 213.63% respectively, dwarfing the Sensex’s 37.89% and 84.19% gains over the same periods. These figures highlight the stock’s strong growth trajectory and invest...

Auro Labs. Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-04 11:08:19

Auro Labs., a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators, including valuation concerns and subdued financial trends, which continue to shape investor perspectives.

Auro Laboratories Surges with Unprecedented Buying Interest, Hits Upper Circuit

2025-11-20 14:20:29

Auro Laboratories Ltd has witnessed extraordinary buying momentum today, registering a sharp surge that propelled the stock to hit its upper circuit limit. The absence of sellers and a queue filled exclusively with buy orders signal a potential multi-day circuit scenario, underscoring robust investor interest in this Pharmaceuticals & Biotechnology company.

Auro Laboratories Shows Stable Performance Amidst Mixed Financial Results and Market Resilience

2025-11-14 11:00:37

Auro Laboratories has reported stable financial performance for the quarter ending September 2025, with net sales reaching Rs 11.61 crore and significant improvements in key metrics. Despite a decline in PAT for the nine-month period, the company has outperformed the Sensex over the past three years.

Auro Laboratories Q2 FY26: Profit Recovery Masks Deeper Structural Concerns

2025-11-14 09:19:50

Auro Laboratories Ltd., a Mumbai-based generic Active Pharmaceutical Ingredients manufacturer specialising in anti-diabetic compounds, reported a return to profitability in Q2 FY26 with net profit of ₹0.72 crores, reversing the ₹0.11 crore loss recorded in the previous quarter. However, the modest absolute profit figure and concerning long-term trends continue to weigh on investor sentiment, with the stock trading at ₹228.00 and carrying a market capitalisation of just ₹142.10 crores.

How has been the historical performance of Auro Labs.?

2025-11-13 23:15:19

Answer: The historical performance of Auro Labs shows a consolidated net profit of 1.84 crore for the year ending March 2025, with total operating income of 19.40 crore. The operating profit margin, excluding other income, stands at 17.58%, while the profit after tax margin is 9.48%. The company has total liabilities of 99.10 crore, with long-term borrowings increasing significantly to 30.79 crore from previous years. The total assets have also risen to 99.10 crore, reflecting growth in shareholder's funds, which reached 42.97 crore. Breakdown: In the fiscal year ending March 2025, Auro Labs reported a total operating income of 19.40 crore, with a net profit of 1.84 crore, indicating a profit after tax margin of 9.48%. The operating profit, excluding other income, was 3.41 crore, leading to an operating profit margin of 17.58%. The company's total liabilities increased to 99.10 crore, driven by a rise in ...

Why is Auro Labs. falling/rising?

2025-11-13 21:41:54

As of 13-Nov, Auro Laboratories Ltd's stock price is rising, currently at Rs 219.40, reflecting an increase of Rs 36.55 or 19.99%. The stock has shown strong performance today, outperforming its sector by 19.78% and opening with a gain of 6.64%. It reached an intraday high of Rs 219.40 and has traded within a wide range of Rs 30. However, despite this positive movement, there has been a notable decline in investor participation, with delivery volume falling by 25.86% compared to the 5-day average. Year-to-date, the stock is down 17.86%, but it has performed well over the past three years with a return of 183.28%. In the broader market context, Auro Laboratories Ltd's short-term return of 17.45% over the past week significantly outpaces the Sensex, which has only increased by 1.40% in the same period. This indicates that the stock is gaining traction relative to the market. However, the year-to-date perform...

Auro Laboratories Ltd Surges 19.99% Today, Reaching Intraday High of Rs 219.4

2025-11-13 11:30:19

Auro Laboratories Ltd is experiencing notable buying activity, with a significant intraday surge. The stock has shown strong weekly gains, contrasting with its recent performance over longer periods. Current investor interest may be linked to developments in the pharmaceutical sector, contributing to heightened trading volatility.

How has been the historical performance of Auro Labs.?

2025-11-13 00:06:02

Answer: The historical performance of Auro Labs shows a significant decline in net sales and profits over the past few years, particularly in the latest fiscal year ending March 2025. Breakdown: Auro Labs reported net sales of 19.40 Cr in March 2025, a sharp decrease from 53.64 Cr in March 2024 and 52.89 Cr in March 2023, indicating a downward trend in revenue. The total operating income followed a similar pattern, dropping to 19.40 Cr in March 2025 from 53.64 Cr in the previous year. The company's operating profit (PBDIT) also fell to 4.07 Cr in March 2025, down from 12.17 Cr in March 2024, reflecting a declining operating profit margin of 17.58%. Profit before tax decreased to 1.88 Cr in March 2025 from 10.35 Cr in March 2024, leading to a profit after tax of 1.84 Cr, down from 7.79 Cr. The total assets of Auro Labs increased to 99.10 Cr in March 2025 from 85.73 Cr in March 2024, while total liabilities ...

View All News

Announcement

Announcement under Regulation 30 (LODR)-Newspaper Publication

14-Nov-2025 | Source : BSE

Auro Laboratories Limited has submitted clippings of Newspaper Publications of the unaudited financial Results for the quarter and half year ended September 30 2025.

Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025

12-Nov-2025 | Source : BSE

Auro Laboratories Limited has submitted unaudited Financial Results for the quarter and half year ended September 30 2025

Grant Of Certificate Of Good Manufacturing Practices From World Health Organisation (WHQ).

12-Nov-2025 | Source : BSE

Auro Laboratories Limited wishes to inform that Company has received World Health Organization - Good Manufacturing Practices (WHO-GMP) Certifcate from Food & Drug Administration.